Decades of research have mapped out the basic mechanics of the Hippo pathway. The
paralogues Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding …

The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …

Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth
factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related …

Cancer is a dynamic disease. During the course of disease, cancers generally become more
heterogeneous. As a result of this heterogeneity, the bulk tumour might include a diverse …

Eradicating tumor dormancy that develops following epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Hippo signaling has been recognized as a key tumor suppressor pathway. Here, we perform
a comprehensive molecular characterization of 19 Hippo core genes in 9,125 tumor …

The transcriptional co‐activators YAP (or YAP1) and TAZ (or WWTR1) are frequently
activated during the growth and progression of many solid tumors, including lung, colorectal …

Tumor cells evade targeted drugs by rewiring their genetic and epigenetic networks. Here,
we identified that inhibition of MAPK signaling rapidly induces an epithelial-to-mesenchymal …